A Phase 3 interventional study of Placebo and Sevelamer Carbonate (GZ419831) in Hyperphosphatemia, sponsored by Sanofi. Completed at 38 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sevelamer in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. Sevelamer · Hyperphosphatemia.
Among the 12 studies testing sevelamer in Hyperphosphatemia, this one is the 3rd largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 10th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →None of the 12 studies testing sevelamer in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →
Sevelamer: first FDA approval 1998 (RENAGEL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2017.
This study's enrollment of 202 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 45 across the 12 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 9 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 7 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing sevelamer in Hyperphosphatemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.
Secondary Objectives:
To document the efficacy of Renvela tablets in the reduction of serum lipids (total cholesterol and low-density lipoprotein cholesterol [LDL-C]).
To document the efficacy of Renvela tablets in the reduction of calcium-phosphorus product.
To document the efficacy of Renvela tablets in the reduction of intact parathyroid hormone (iPTH).
To document the efficacy of Renvela tablets in proportion of participants reaching the target serum phosphorus level 4.6 milligrams per decilitre (mg/dL) (1.47 millimoles per litre [mmol/L], inclusive).
To evaluate safety of Renvela tablets.
The total duration of study period per participant was up to 14 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Had the following laboratory measurements at screening visit:
Exclusion criteria:
Conditions/situations such as:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (\<=) 4.6 mg/dL (\<=1.49 mmol/L).
Drug: Placebo
Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus \<=4.6 mg/dL (\<=1.49 mmol/L).
Drug: Sevelamer Carbonate (GZ419831)
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Also known as: Renvela
Change From Baseline in Serum Phosphorus at Week 8
Baseline of serum phosphorus value was the last serum phosphorus level obtained before the first double-blind investigational medicinal product (IMP) dosing. Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.
Time frame: Baseline, Week 8
Change From Baseline in Total Cholesterol at Week 8
Missing Week 8 data were imputed by LOCF method.
Time frame: Baseline, Week 8
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8
Missing Week 8 data were imputed by LOCF method.
Time frame: Baseline, Week 8
Change From Baseline in Calcium-Phosphorus Product at Week 8
Missing Week 8 data were imputed by LOCF method.
Time frame: Baseline, Week 8
Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8
Missing Week 8 data were imputed by LOCF method.
Time frame: Baseline, Week 8
Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8
Missing Week 8 data were imputed by LOCF method.
Time frame: Week 8
Change From Baseline in Serum Phosphorus Level at Week 4
Missing Week 4 data were imputed by LOCF method.
Time frame: Baseline, Week 4
Number of Participants With Treatment Emergent Adverse Event
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an Adverse Event (AE) without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during TEAE period. On-treatment period was defined as the (time from the first dose of IMP to the last dose of IMP+3 days). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female \[F\]); \>=185 g/L (M) or \>=165 g/L (F); Decrease from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Triglycerides: \>=4.6 mmol/L * Albumin: \<= 25 g/L.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Laboratory Abnormalities: Electrolytes
Criteria for potentially clinically significant abnormalities: Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L Potassium: \<3 mmol/L; \>=5.5 mmol/L Chloride: \<80 mmol/L; \>115 mmol/L.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Laboratory Abnormalities: Renal Function Parameters
Criteria for potentially clinically significant abnormalities: Creatinine: \>=150 micromol/L; \>=30% change from baseline, \>=100% change from baseline Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min Blood urea nitrogen: \>=17 mmol/L Uric acid: \<120 micromol/L; \>408 micromol/L Glomular Filtration Rate (GFR): \< 15 mL/min/1.73m\^2, \>= 15 - \< 30 mL/min/1.73m\^2, \>= 30 - \< 60 mL/min/1.73m\^2, \>= 60 - \< 90 mL/min/1.73m\^2.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Criteria for potentially clinically significant abnormalities: Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN; Aspartate aminotransferase (AST): \>3 ULN.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Number of Participants With Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm Weight: \>=5% DFB; \>=5% IFB.
Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Study was conducted at 38 centers in China. A total of 482 participants were screened between 07 June 2017 \& 30 May 2019, of which 280 participants were screen failures. Screen failures were mainly due to serum phosphorus level greater than or equal to \>=5.5 milligrams per deciliter (mg/dL) (1.78 millimoles per litre \[mmol/L\]) at screening visit.
| Milestone | Placebo | Renvela |
|---|---|---|
| Started | 101 | 101 |
| Completed | 74 | 80 |
| Not completed | 27 | 21 |
| Withdrew: Adverse event | 9 | 3 |
| Withdrew: Chronic kidney disease lead to dialysis | 15 | 10 |
| Withdrew: Other than specified above | 3 | 8 |
Baseline of serum phosphorus value was the last serum phosphorus level obtained before the first double-blind investigational medicinal product (IMP) dosing. Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.
| mmol/L | Placebo | Renvela |
|---|---|---|
| Baseline | 2.090 (1.870 to 2.270) | 2.095 (1.870 to 2.400) |
| Change at Week 8 | 0.010 (-0.200 to 0.250) | -0.200 (-0.490 to 0.020) |
Missing Week 8 data were imputed by LOCF method.
| mmol/L | Placebo | Renvela |
|---|---|---|
| Change From Baseline in Total Cholesterol at Week 8 | -0.115 (-1.82 to 1.54) | -0.830 (-4.45 to 0.74) |
Missing Week 8 data were imputed by LOCF method.
| mmol/L | Placebo | Renvela |
|---|---|---|
| Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 | -0.030 (-1.61 to 1.30) | -0.830 (-3.31 to 0.51) |
Missing Week 8 data were imputed by LOCF method.
| mmol^2/L^2 | Placebo | Renvela |
|---|---|---|
| Change From Baseline in Calcium-Phosphorus Product at Week 8 | 0.0200 (-2.648 to 2.936) | -0.4960 (-2.592 to 2.696) |
Missing Week 8 data were imputed by LOCF method.
| nanogram per liter (ng/L) | Placebo | Renvela |
|---|---|---|
| Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8 | 7.2380 (-298.732 to 573.306) | 0.0000 (-370.172 to 327.966) |
Missing Week 8 data were imputed by LOCF method.
| percentage of participants | Placebo | Renvela |
|---|---|---|
| Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8 | 6.6 | 15.5 |
Missing Week 4 data were imputed by LOCF method.
| mmol/L | Placebo | Renvela |
|---|---|---|
| Change From Baseline in Serum Phosphorus Level at Week 4 | -0.020 (-1.56 to 2.42) | -0.240 (-1.03 to 1.39) |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an Adverse Event (AE) without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during TEAE period. On-treatment period was defined as the (time from the first dose of IMP to the last dose of IMP+3 days). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.
| Participants | Placebo | Renvela |
|---|---|---|
| Any TEAE | 86 | 83 |
| Any Treatment emergent SAE | 31 | 26 |
| any TEAE leading to permanent discontinuation | 21 | 12 |
Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female \[F\]); \>=185 g/L (M) or \>=165 g/L (F); Decrease from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)
| Participants | Placebo | Renvela |
|---|---|---|
| Hemoglobin <=115 g/L (M) or <=95 g/L (F) | 59 | 54 |
| Hemoglobin >=185 g/L (M) or >=165 g/L (F) | 0 | 0 |
| Hemoglobin DFB >=20 g/L | 9 | 6 |
| Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F) | 68 | 67 |
| Hematocrit >0.55 v/v (M) or >=0.5 v/v (F) | 0 | 0 |
| RBC >=6 Tera/L | 0 | 1 |
| Platelets <100 Giga/L | 3 | 4 |
| Platelets >=700 Giga/L | 0 | 0 |
| WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 2 | 0 |
| WBC >=16.0 Giga/L | 0 | 0 |
| Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 | 0 |
| Lymphocytes >4 Giga/L | 0 | 0 |
| Monocytes >0.7 Giga/L | 0 | 0 |
| Basophils >0.1 Giga/L | 0 | 0 |
| Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L) | 4 | 6 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Triglycerides: \>=4.6 mmol/L * Albumin: \<= 25 g/L.
| Participants | Placebo | Renvela |
|---|---|---|
| Triglycerides: >=4.6 mmol/L | 0 | 2 |
| Glucose: =< 3.9 mmol/L and < LLN | 1 | 1 |
| Glucose: >=11.1 mmol/L(unfas); >=7 mmol/L(fas) | 5 | 6 |
| Albumin: <= 25 g/L | 1 | 0 |
Criteria for potentially clinically significant abnormalities: Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L Potassium: \<3 mmol/L; \>=5.5 mmol/L Chloride: \<80 mmol/L; \>115 mmol/L.
| Participants | Placebo | Renvela |
|---|---|---|
| Sodium <=129 mmol/L | 1 | 3 |
| Sodium >=160 mmol/L | 0 | 0 |
| Potassium <3 mmol/L | 0 | 0 |
| Potassium >=5.5 mmol/L | 36 | 46 |
| Chloride <80 mmol/L | 0 | 2 |
| Chloride >115 mmol/L | 0 | 0 |
Criteria for potentially clinically significant abnormalities: Creatinine: \>=150 micromol/L; \>=30% change from baseline, \>=100% change from baseline Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min Blood urea nitrogen: \>=17 mmol/L Uric acid: \<120 micromol/L; \>408 micromol/L Glomular Filtration Rate (GFR): \< 15 mL/min/1.73m\^2, \>= 15 - \< 30 mL/min/1.73m\^2, \>= 30 - \< 60 mL/min/1.73m\^2, \>= 60 - \< 90 mL/min/1.73m\^2.
| Participants | Placebo | Renvela |
|---|---|---|
| Creatinine >=150 micromol/L | 84 | 89 |
| Creatinine >=30% change from baseline | 15 | 33 |
| Creatinine >=100% change from baseline | 3 | 3 |
| Creatinine Clearance <15 mL/min | 77 | 81 |
| Creatinine clearance >=15 to <30 mL/min | 6 | 8 |
| Creatinine clearance >=30 to <60 mL/min | 1 | 0 |
| Creatinine clearance >=60 to <90 mL/min | 0 | 0 |
| Blood Urea Nitrogen >=17 mmol/L | 77 | 83 |
| Uric acid <120 micromol/L | 0 | 0 |
| Uric acid >408 micromol/L | 56 | 67 |
| GFR < 15 mL/min/1.73m^2 | 82 | 86 |
| GFR >= 15 - < 30 mL/min/1.73m^2 | 2 | 3 |
| GFR >= 30 - < 60 mL/min/1.73m^2 | 0 | 0 |
| GFR >= 60 - < 90 mL/min/1.73m^2 | 0 | 0 |
Criteria for potentially clinically significant abnormalities: Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN; Aspartate aminotransferase (AST): \>3 ULN.
| Participants | Placebo | Renvela |
|---|---|---|
| ALT >3 ULN | 1 | 0 |
| ALT >5 ULN | 1 | 0 |
| ALT >10 ULN | 0 | 0 |
| AST >3 ULN | 0 | 0 |
Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm Weight: \>=5% DFB; \>=5% IFB.
| Participants | Placebo | Renvela |
|---|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 0 | 0 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 17 | 12 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 0 | 0 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 2 | 3 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 0 | 0 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 0 | 0 |
| Weight >=5% DFB | 12 | 7 |
| Weight >=5% IFB | 14 | 9 |
Collected over Reported AEs are TEAEs that is AEs that developed/worsened or became serious during the TEAE period (time from the first dose of IMP to the last dose of IMP+3 days i.e. Day 59).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/101 (0%) | 31/101 (30.7%) | 52/101 (51.5%) |
| Renvela | 0/101 (0%) | 26/101 (25.7%) | 60/101 (59.4%) |
| Event | Placebo | Renvela |
|---|---|---|
| Chronic Kidney DiseaseRenal and urinary disorders | 13/101 | 8/101 |
| End Stage Renal DiseaseRenal and urinary disorders | 7/101 | 9/101 |
| AzotaemiaRenal and urinary disorders | 4/101 | 1/101 |
| Lung InfectionInfections and infestations | 2/101 | 2/101 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/101 | 2/101 |
| AnaemiaBlood and lymphatic system disorders | 1/101 | 0/101 |
| Angina PectorisCardiac disorders | 1/101 | 0/101 |
| Cardiac FailureCardiac disorders | 1/101 | 1/101 |
| Cardiac Failure AcuteCardiac disorders | 1/101 | 0/101 |
| CataractEye disorders | 0/101 | 1/101 |
| Event | Placebo | Renvela |
|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 18/101 | 25/101 |
| NauseaGastrointestinal disorders | 15/101 | 10/101 |
| Oedema PeripheralGeneral disorders | 9/101 | 14/101 |
| VomitingGastrointestinal disorders | 13/101 | 12/101 |
| Decreased AppetiteMetabolism and nutrition disorders | 11/101 | 4/101 |
| Upper Respiratory Tract InfectionInfections and infestations | 9/101 | 8/101 |
| DiarrhoeaGastrointestinal disorders | 8/101 | 5/101 |
| HypocalcaemiaMetabolism and nutrition disorders | 8/101 | 3/101 |
| ConstipationGastrointestinal disorders | 5/101 | 7/101 |
| Metabolic AcidosisMetabolism and nutrition disorders | 7/101 | 4/101 |
Analysis was performed on randomized participants.
| Age, Continuous(years) | Placebo | Renvela | Total |
|---|---|---|---|
| Mean | 50.9 ± 12.4 | 50.6 ± 13.5 | 50.7 ± 12.9 |
| Sex: Female, Male(Participants) | Placebo | Renvela | Total |
|---|---|---|---|
| Female | 46 | 48 | 94 |
| Male | 55 | 53 | 108 |
| Race (NIH/OMB)(Participants) | Placebo | Renvela | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 101 | 101 | 202 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jun 2017 to primary completion in Aug 2019, 26 months.
Results were first posted in Jul 2020, 11 months after primary completion.
Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevelamer